Bank of Montreal Can reduced its position in shares of Retrophin, Inc. (NASDAQ:RTRX) by 9.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,184 shares of the biopharmaceutical company’s stock after selling 11,682 shares during the period. Bank of Montreal Can owned approximately 0.30% of Retrophin worth $2,195,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. American International Group Inc. raised its stake in Retrophin by 7.1% in the first quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 1,475 shares during the last quarter. Credit Suisse AG raised its stake in shares of Retrophin by 8.4% in the first quarter. Credit Suisse AG now owns 57,025 shares of the biopharmaceutical company’s stock valued at $1,052,000 after buying an additional 4,407 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Retrophin by 12.8% in the first quarter. Wells Fargo & Company MN now owns 50,785 shares of the biopharmaceutical company’s stock valued at $938,000 after buying an additional 5,763 shares in the last quarter. Weiss Multi Strategy Advisers LLC acquired a new stake in shares of Retrophin during the first quarter valued at about $185,000. Finally, Tudor Investment Corp ET AL raised its stake in shares of Retrophin by 19.5% in the first quarter. Tudor Investment Corp ET AL now owns 61,733 shares of the biopharmaceutical company’s stock valued at $1,140,000 after buying an additional 10,067 shares in the last quarter.

Shares of Retrophin, Inc. (NASDAQ RTRX) traded up 5.66% during midday trading on Friday, hitting $21.83. The stock had a trading volume of 373,941 shares. Retrophin, Inc. has a 12 month low of $15.55 and a 12 month high of $24.57. The stock’s market cap is $837.94 million. The stock’s 50-day moving average is $19.89 and its 200-day moving average is $19.04.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.10. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business had revenue of $38.80 million during the quarter, compared to analysts’ expectations of $37.36 million. During the same quarter in the prior year, the firm earned $0.07 EPS. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year. Equities analysts anticipate that Retrophin, Inc. will post ($1.13) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://theolympiareport.com/2017/08/12/bank-of-montreal-can-has-2-20-million-position-in-retrophin-inc-rtrx.html.

Several brokerages have recently issued reports on RTRX. ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. TheStreet raised Retrophin from a “d” rating to a “c-” rating in a research report on Friday, May 12th. Finally, Zacks Investment Research lowered Retrophin from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Retrophin presently has a consensus rating of “Buy” and an average price target of $32.25.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.